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Abstract
Background: The average life expectancy for people with a severe mental illness (SMI) such as schizophrenia or bipolar disorder
is 15 to 20 years less than that for the population as a whole. Diabetes contributes significantly to this inequality, being 2 to 3
times more prevalent in people with SMI. Various risk factors have been implicated, including side effects of antipsychotic
medication and unhealthy lifestyles, which often occur in the context of socioeconomic disadvantage and health care inequality.
However, little is known about how these factors may interact to influence the risk of developing diabetes and poor diabetic
outcomes, or how the organization and provision of health care may contribute.
Objective: This study aims to identify the determinants of diabetes and to explore variation in diabetes outcomes for people
with SMI.
Methods: This study will employ a concurrent mixed methods design combining the interrogation of electronic primary care
health records from the Clinical Practice Research Datalink (CPRD GOLD) with qualitative interviews with adults with SMI and
diabetes, their relatives and friends, and health care staff. The study has been funded for 2 years, from September 2017 to September
2019, and data collection has recently ended.
Results: CPRD and linked health data will be used to explore the association of sociodemographics, illness, and health care–related
factors with both the development and outcomes of type 2 diabetes in people with SMI. Experiences of managing the comorbidity
and accessing health care will be explored through qualitative interviews using topic guides informed by evidence synthesis and
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expert consultation. Findings from both datasets will be merged to develop a more comprehensive understanding of diabetes
risks, interventions, and outcomes for people with SMI. Findings will be translated into recommendations for interventions and
services using co-design workshops.
Conclusions: Improving diabetes outcomes for people with SMI is a high-priority area nationally and globally. Understanding
how risk factors combine to generate high prevalence of diabetes and poor diabetic outcomes for this population is a necessary
first step in developing health care interventions to improve outcomes for people with diabetes and SMI.
Trial Registration: ClinicalTrials.gov NCT03534921; https://clinicaltrials.gov/ct2/show/NCT03534921
(JMIR Res Protoc 2019;8(9):13407)  doi: 10.2196/13407
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Introduction
Background
Severe mental illness (SMI) refers to a set of disabling
conditions such as schizophrenia, schizoaffective disorder, or
bipolar disorder. People with SMI, who account for around 1%
of the population [1], may experience feelings of persecution,
hallucinations, problems with mood, impaired cognition, and
lack of motivation. These difficulties can have an adverse impact
on several areas of life such as housing, employment,
relationships, and personal care, which can, in turn, increase
the likelihood of mental and physical health problems. They
have a reduced life expectancy, living for 15 to 20 years less
than the population as a whole, and experience poorer health
outcomes [2-5].
Diabetes is a significant contributor to the increased morbidity
and mortality experienced by people with SMI. The condition
is 2 to 3 times more prevalent in this population [6-8], and
complications of diabetes are higher than for people without
SMI [9,10]. The link between the metabolic side-effects of
antipsychotic medication and diabetes has been
well-documented [11-13], but there are additional complexities;
other work points to the possibility of a genetic
neuroinflammatory mechanism predisposing people toward
both conditions [14], which could explain the occurrence of the
comorbidity independent of antipsychotic medication [15,16].
Furthermore, other factors have been implicated such as lifestyle
health risk factors such as diet [17], smoking [18,19], low levels
of physical activity [20], and higher levels of other comorbid
conditions [21]. However, little is known about the relative
contribution of these factors, or about possible synergistic
relationships that may increase the risk of people with SMI
developing diabetes or experiencing poorer diabetes outcomes.
There is strong evidence that people with SMI are more likely
to be socially disadvantaged than people without SMI [22-24],
experiencing reduced access to material, financial, social, or
structural resources such as transport, childcare, paid leave, and
advocacy services [25]. Accordingly, people with SMI have
difficulty navigating health care systems, less capacity to take
advantage of health promotion opportunities, and encounter
more barriers to taking up interventions designed to prevent or
treat illness. Moreover, despite calls for integrated service
models that treat the whole person [26], such models of service
delivery can be thwarted by rigid boundaries between primary
and secondary care, unclear practitioner accountability for
mental and physical health care [27,28], and diagnostic
overshadowing (misattributing physical health problems to
mental illness) [29].
There is conflicting evidence about the quality of diabetes care
for those with and without SMI [10,30-34]. In addition, little is
known about the costs of diabetes screening, monitoring, and
management for this group, or about the relationship between
diabetes interventions and health outcomes. Furthermore,
although a recent study demonstrated that diabetes distress—the
emotional burden of managing a serious, chronic condition—is
known to significantly affect people with diabetes who do not
have SMI [35], there is limited evidence on how diabetes might
impact upon the mental health of people who already experience
psychological vulnerabilities.
Improving diabetes care for people with SMI is a high priority
nationally and globally [36,37]. Understanding how SMI and
other risk factors combine to generate high diabetes prevalence
and poor diabetes outcomes and how the quality and quantity
of health care services and interventions can impact on these
risk factors is a necessary first step in developing health care
interventions to improve outcomes for people with diabetes and
SMI.
Objectives
This study aims to identify the determinants of diabetes in
people with SMI and to explore variation in diabetes outcomes
for people with SMI to develop potential health care
interventions that can be tested further.
The study has the following objectives:
1. In people with SMI, to identify which sociodemographic,
illness, family history, and lifestyle factors are associated
with the development of diabetes
2. In people with SMI and diabetes, to identify which
sociodemographic, illness, family history, and lifestyle
factors are associated with variation in diabetes and mental
health outcomes
3. In people with SMI, to compare health care interventions,
physical and mental health outcomes in those with diabetes,
and those without diabetes
4. In people with diabetes, to compare health care
interventions, physical and mental health outcomes in those
with SMI, and those without SMI
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5. To understand the factors that influence access to, and
receipt of, diabetes care for people with SMI and explore
the experience of diabetes health care by people with SMI
6. To compare diabetes care provision for people with and
without SMI, and estimate costs for these
7. To identify which health care interventions (eg, medication,
referrals, and care pathways) may be associated with better
diabetes outcomes for people with SMI and diabetes.
Methods
Design
The underpinning theoretical framework for the study
conceptualizes socioeconomic conditions as a fundamental
cause of health inequalities [25]. Under a social inequalities
framework, a concurrent triangulation mixed methods design
will be used comprising (1) a quantitative longitudinal
observational study of anonymized individual patient records
of adults diagnosed with SMI in Clinical Practice Research
Datalink (CPRD) and (2) a qualitative interview study of people
with coexisting SMI and diabetes, their family or friends, and
health care staff involved in diabetes and mental health care.
Both workstreams will be informed by a synthesis of existing
evidence.
The mixed methods design is underpinned by a pragmatic
paradigm, which acknowledges that data types, when integrated
together, will enable the development of a more complete
understanding of health inequalities in this population than
would be possible from either method alone [38]. Interrogation
of quantitative data from CPRD will be used to generate insights
into inequalities through identifying trends, patterns, and
correlations, indicating which groups are more at risk of
developing diabetes or experiencing poor diabetes outcomes.
These data will be complemented by findings from the analysis
of qualitative interviews conducted to explore the difficulties
people with SMI have in managing their diabetes and accessing
services. The quantitative and qualitative data will be integrated
iteratively as the study progresses; key findings emerging from
the CPRD analysis will be explored further in interviews, and
qualitative themes will be used to inform the choice of variables
that can be explored in the quantitative dataset (see Figure 1).
Key to both the quantitative and qualitative analyses will be
exploring the effects of disadvantage and deprivation on risks,
outcomes, and experiences for people with SMI and diabetes.
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Figure 1. Study Flow Diagram.
Patient and Public Involvement
The study is supported by DIAMONDS VOICE, a patient and
public involvement (PPI) panel that contributes to a wider
research program called Diabetes and Mental Illness: Improving
Outcomes and Services. The panel was involved in prioritizing
the research questions during the design phase of this study and
reviewed all patient and public-facing documentation before
submission to the National Health Service Research Ethics
Committee. The panel will continue to contribute to the study
in the following ways: advising on how to ask sensitive
questions, acting as practice interviewees, advising on
minimizing participant burden, promoting the study at local
events, and advising on recruitment and dissemination strategies.
Both the project management team and the study steering
committee have service user representation to ensure that the
patient perspective is incorporated in project decisions.
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Ethical Approval and Data Use Agreement
A data use agreement for CPRD records and linked Hospital
Episode Statistics (HES) and Office for National Statistics
(ONS) mortality data was granted by the International Scientific
Advisory Committee (ref: 17_161R). Approvals for the
qualitative study were granted by the National Institute of Health
Research Health Research Authority and the Greater Manchester
West Research Ethics Committee (ref: 18/NW/0005), following
a submission made through the Integrated Research Application
System (ref: 235328).
The study is registered on the NIHR Central Portfolio
Management System (CPMS; ref: #37024) and
ClinicalTrials.gov (record identifier #NCT03534921).
Quantitative, Longitudinal, and Observational Study
This workstream examines the impact of potential risk factors
on the development and the time to onset of diabetes in people
with SMI and variation in mental and physical health outcomes
in people with comorbid SMI and diabetes. Diabetes health care
and outcomes for people with SMI and diabetes will be
compared with outcomes for people with either condition alone.
Variations in diabetes screening, monitoring, and management
will be examined and costs estimated. The role of these
interventions in contributing to health outcomes will be
explored.
Study Population
The primary study population comprises adult patients (age ≥18
years) living in England who are registered with a general
practice contributing up to research standard data to CPRD and
who have remained within CPRD for the study period, from
April 1, 2000, to March 31, 2016.
Datasets
CPRD is the world’s largest computerized database of
anonymized longitudinal medical records from primary care.
Information includes records of symptoms, diagnoses, referrals,
prescriptions issued in primary care, records of immunizations
and vaccinations, laboratory test results, lifestyle information
(eg smoking and alcohol status), and all other types of care
administered as part of routine general practice. Currently, data
are collected on over 5 million active patients from 674 general
practices, covering around 6.9% of the UK population registered
with a general practitioner [39].
Records for 3 population groups will be extracted from CPRD.
The datasets will be structured as shown in Table 1.
Data Linkages
Electronically linked data for individuals in the study population
will be obtained from the following sources: HES data for
hospital admissions [41], ONS for dates and causes of death
[42], and the Index of Multiple Deprivation (IMD) for area
deprivation at practice and patient level [43].
Health and Health Care Outcomes
The following outcomes listed in Table 2, corresponding to the
objectives described above, will be examined.
Analyses may be limited by the quality and availability of data
for some of the above variables, but wherever possible, validated
code lists will be employed.
Table 1. Structure of the Clinical Practice Research Datalink datasets.
Estimated sample size of
patients
SpecificationPopulationDataset
33,000Longitudinal health care records of adult patients with SMI defined
as the presence of a clinical diagnostic code for schizophrenia, af-
fective disorder (divided into bipolar or unspecified affective dis-
order), and other types of psychoses. Read codes previously tested
and applied by the research team [37] will be used to identify the
presence of SMI.
Adults (≥18 years) with
SMIa
Dataset A
3600 based on a predicted
diabetes prevalence of
11.1% [40]
Diabetes, identified using previously tested and validated Read
codes, will be further defined as the presence of a clinical diagnos-
tic code for type 1 diabetes, type 2 diabetes, drug-induced diabetes,
or unspecified diabetes. Individuals with a diagnostic code of
gestational diabetes, cystic fibrosis, and hemochromatosis will be
excluded.
Adults with a diagnosis of
SMI and diabetes mellitus
Dataset B (a subset
of dataset A)
14,400Patients with type 2 diabetes in dataset B will be matched by
Clinical Practice Research Datalink to a cohort of patients who
have a diagnosis of type 2 diabetes but without SMI (controls)
with a case to control ratio of 1:4 on the basis of age, gender, and
practice.
Adults with a diagnosis of
type 2 diabetes but without
SMI
Dataset C (matched
controls to dataset
B)
aSMI: severe mental illness.
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Table 2. Health and health care outcomes corresponding to objectives.
Objective #Outcome
1Diabetes status and onset
2Diabetic and cardiovascular control (measured by recorded hemoglobin A1c, blood pressure, and cholesterol levels)
2, 4Diabetic complications: acute hyperglycemic events, hypoglycemia, microvascular complications (retinopathy, neuropathy, and
nephropathy)
2, 3, 4, 7Diabetic complications: macrovascular complications (coronary artery disease, cerebrovascular disease, and peripheral arterial disease)
2, 3, 4, 7Hospital admissions for the above conditions
2, 3, 4, 7Mental health outcomes including severe mental illness relapses (measured by hospital admissions and general practitioner referrals
to community mental health teams or crisis teams) and markers of depression or anxiety (ie, general practitioner diagnoses or prescriptions
for antidepressants)
2, 3, 4, 7Mortality
6Health care utilization (including the number and type of primary care consultations) and costs
6, 7Health care interventions (eg, first and second generation antipsychotic and antidiabetic medications, care pathways, and referrals)
Risk Factors and Explanatory Variables
Known risk factors and covariates for developing diabetes and
diabetes complications will be included in the analyses to
determine their relative association with the development and
progress of diabetes in people with SMI. The list of factors will
be determined by evidence synthesis, complemented by expert
consensus, and will be responsive to emerging findings from
the qualitative interviews.
The candidate risk factors include patient demographics and
socioeconomic markers (sex, age, ethnic group, area deprivation,
and rurality), lifestyle (obesity, smoking, and alcohol
consumption), social vulnerability markers such as housing
status, hyperlipidemia, family history, type of SMI and diabetes
(including order and timing of diagnosis), length of diagnosis,
illness severity, and multimorbidity.
Statistical Analysis
It is anticipated that there will be around 5 to 6 years of data on
each individual, which will enable more robust analyses than
cross-sectional data would permit. Longitudinal data afford
better control for unobserved characteristics, at either the
individual or practice level that plausibly impact both practice
performance and patient outcomes (eg, practice style and
culture), and which may otherwise confound important
relationships. In addition, repeated observations at practice or
patient level allow the investigation of lags in the relationship
between diabetes management and outcomes, as the timing of
events can be observed. Both these factors are crucial in
identifying plausible causal mechanisms linking diabetes
management to outcomes.
The potential for confounding will be addressed by matching
on index date to avoid inclusion of ghost patients, conducting
sensitivity analyses, and evaluating the potential for unmeasured
confounding and the size of any observed effects.
A range of regression models will be used for statistical
analyses, taking account of the hierarchical structure of the data,
where, for example, activities are nested within patients who in
turn are nested within practices. Linear, logistic and survival
regressions will be applied as appropriate depending on the
outcome variable of interest. Multilevel mixed effects will be
estimated to account for the correlation in the longitudinal health
records of the same patient, as well as the unobserved correlation
at practice level. An outline of planned analyses by study
objective is given in Table 3.
Under all objectives, analyses will be conducted in line with
the inequalities framework to quantify the absolute and relative
effect of social inequalities on quality of care and outcomes.
Under objectives 1 and 3, the disparities will be modeled within
the SMI population, under objective 2 within the SMI and
diabetes population, and both within and between the diabetes
populations (SMI and non-SMI) under objectives 4 to 7.
Specifically, where sample size permits, analyses will be
stratified, for example, by ethnicity and or deprivation and
disadvantage markers such as IMD; housing status and rurality
will be used as independent variables to estimate gap or gradient
effects.
All statistical models will include a set of relevant patient, local
population, and practice covariates where possible to control
for confounding and interacting influences potentially masking
the relationship between diabetes management and outcomes.
In sensitivity analyses, noncompliance (including refusal of
treatment, informed dissent, and nonattendance) will be included
as an independent variable in the models. Sensitivity analyses
will be conducted with noncompliance treated as either a
time-dependent (expiring) or time-independent (nonexpiring)
variable and as specific to the refused treatment or as a general
marker of noncompliance. Noncompliance will be used to create
offer of treatment explanatory variables, facilitating
intention-to-treat type analyses.
Robustness checks will be carried out to ensure our results are
reliable, and plausibility tests to ensure findings are meaningful
in practice and can inform policy. Model assumptions will be
checked for all analyses, and if they are in doubt, the data will
be transformed before analysis or alternative nonparametric
analysis methods will be used.
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Table 3. Summary of statistical analysis plan by study objective.
AnalysisVariablesDatasetsDescriptionObjective #a
Multilevel modeling: logistic model (dia-
betes status) and survival model (time to
diabetes onset)
Explanatory variables: sociodemographic
characteristics, medication use, physical
and mental health status, family history of
diabetes, biometric data dysregulation, and
lifestyle factors
Quantitative
dataset A
(people with
SMIb)
The impact of key explanatory
variables on both diabetes sta-
tus and time to onset of dia-
betes
1
Repeated measures mixed models: linear,
logistic, and survival models
Outcomes: diabetic and cardiovascular
control; diabetic complications; hospital
admissions; mental health outcomes, for
example relapses and episodes of depres-
sion and anxiety and mortality
Quantitative
dataset B
(people with
SMI and
type 2 dia-
betes)
The impact of key explanatory
variables (as above) on diabetes
and mental health outcomes
2
Poisson or negative binomial multilevel
models for count outcomes, logistic multi-
level models for binary outcomes
Outcomes: macrovascular diabetic compli-
cations, hospital admissions, mental health
outcomes, and mortality
Quantitative
dataset A
The impact of diabetes status
and other explanatory variables
(as above) on physical and
mental health outcomes
3
Similar multilevel modeling to objective
3
Outcomes as aboveQuantitative
datasets B
and C
(matched co-
hort of non-
SMI patients
with dia-
betes)
The impact of SMI status and
other explanatory variables (as
above) on physical and mental
health outcomes
4
Cost data will be modeled on patient level
as a nonlinear function (such as exponen-
tial) of covariates to take into account the
nonnegative, highly skewed, and leptokur-
tic characteristics. We will choose the
model depending on the distribution of the
cost data. Random intercepts will be esti-
mated to capture the baseline differences
in health care provision at practice level.
Contacts with primary care staff and hos-
pitalization but not medication costs:
Health care costs will be calculated by at-
taching unit costs to contacts recorded in
the Clinical Practice Research Datalink
database and also hospital inpatient
episodes, from the linked Hospital Episode
Statistics data. National average costs will
be calculated using National Health Ser-
vice Reference Costs and Personal Social
Services Research Unit costs.
Quantitative
datasets B
and C
Comparison of, and cost estima-
tion for, diabetes health care
provision for people with and
without SMI
6
The probability of receiving interventions
will be modeled as a function of SMI sta-
tus, patient characteristics, and other key
predictors. Random intercepts at practice
level will be included in the model to
capture the systematic differences in ser-
vice provision.
Diabetes interventions, for example, regu-
lar reviews, monitoring, referral to educa-
tion programs, foot checks, retinopathy
screening, and referrals to secondary care.
Outcomes, for example, diabetes admis-
sions and diabetic complications
Quantitative
datasets B
and C
Impact of SMI status and other
explanatory variables (as
above) on whether or not
someone receives a diabetes
intervention
7
aObjective number 5 will be explored in the qualitative workstream.
bSMI: severe mental illness.
Qualitative Interview Study
Under the inequalities framework, the qualitative study aims to
develop understandings of the factors that influence access to
and receipt of diabetes care and how health care service
provision is perceived by people living with SMI and diabetes,
those who support them, and health care professionals. The
interviews will be conducted in person or over the telephone,
using topic guides that have been informed by expert
consultation, existing literature, and preliminary CPRD analyses.
Population
Study participants will include (1) adults with SMI and diabetes
(excluding gestational diabetes) living in the community
(n=30-50), (2) relatives or friends who are involved in the care
of a person with SMI and diabetes (n=15-20), and (3) health
care staff (commissioners, clinicians, nurses, and other health
care staff who are involved in health care services for people
with SMI and diabetes; n=15-20).
Sampling
People with SMI and diabetes will be included in the study if
they are:
• Aged 18 years or older
• Diagnosed with a SMI and not currently experiencing an
acute relapse
• Have a diagnosis of diabetes (excluding gestational
diabetes)
• Live in the community
• Have capacity to consent to the study.
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Maximum variation purposive sampling will be used, informed
by demographic and illness characteristics identified during the
descriptive analysis of CPRD data and the social inequalities
theoretical framework to gain understandings of the diversity
of experience in this group. People with SMI and diabetes will
be sampled from rural and urban areas, areas of wealth and
deprivation, and areas with diverse communities.
To ensure representation from different health care disciplines,
health care staff will be sampled purposively. GPs, practice
nurses, diabetes nurses, mental health nurses, case managers,
psychiatrists, and diabetologists will be invited to take part in
the study.
The sampling strategy in all groups will be continually
monitored as the study progresses to ensure that diversity of
experience is captured. Recruitment will continue until data
saturation is reached, that is, no new themes are emerging from
the interviews [44].
Recruitment
Evidence suggests that around 20 to 30% of people with SMI
are supported solely within primary care [45]. Therefore, to
understand how people with SMI experience diabetes care, it
is important to sample from both general practices and specialist
mental health services. Patients and relatives will be identified
by general practice and mental health service staff using
database and caseload searches. Following screening by a
clinician, eligible patients will be sent a study pack containing
an invitation letter, a participant information sheet, a response
form, and a prepaid return envelope.
Patients will also be recruited via existing research cohorts and
clinic and website advertisements. Patients from existing cohorts
who have agreed to be contacted for future research will receive
a study pack. Patients or relatives who express an interest in
participating after seeing an advertisement will also be provided
with the pack. Patients who contact the study team will be asked
to provide permission to access medical records to screen for
eligibility.
To recruit relatives or friends to the study, participating patients
will be asked to identify a person who supports them who will
then be approached by the research team. Relatives who are
known to clinicians will also be provided with a study pack.
For health care staff recruitment, lead clinicians in participating
general practices and mental health services will be asked to
identify health care staff with experience of providing services
to this population.
Consent
Written or audio-recorded informed consent will be obtained
from all participants. Study information will be provided (written
and verbal) using materials that have been developed with the
PPI Group. Capacity to participate will be assessed by staff with
appropriate experience during contact telephone calls and again
before interview.
Data Collection
All interviews will be conducted using semistructured topic
guides (see Table 4), which will be informed by the evidence
synthesis and consultation with the PPI Group and the project
team. Data collection will begin in April 2018, and it is
anticipated that it will be completed by the end of December
2018. The topic guide will be reshaped iteratively as the project
progresses, being influenced by developing themes, CPRD
analyses, and new evidence that emerges in the field.
Interviews will be conducted by an experienced qualitative
researcher and will last for a maximum of 90 min (patients and
relatives) or 45 min for health care staff. With participants’
permission, interviews will be audio-recorded.
Table 4. Qualitative interview topics by participant group.
Topic areasParticipant group
Patients with severe mental illness and diabetes • Emergence of the conditions and experience of diagnosis
• Day-to-day experiences of living with the comorbidities including self-management and
how morbidities impact one another
• Experience of accessing and receiving health or other support services
• Suggestions for improvements to services
Relatives and friends who provide support • Experiences of providing support
• The impact of the comorbidity on shared activities of daily life
• Perceptions of support received from formal services for the person they care for and
themselves
• Perceptions of barriers and facilitators to accessing care
• Suggestions for improvements to services
Health care staff • Role in supporting people living with this comorbidity
• Perceptions of the challenges faced by people living with the comorbidity
• Perceptions of barriers and facilitators to integrating physical and mental health services
• Perceptions of staff training needs
• Suggestions for improvements to services
JMIR Res Protoc 2019 | vol. 8 | iss. 9 | 13407 | p. 8http://www.researchprotocols.org/2019/8/e13407/
(page number not for citation purposes)
Bellass et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Data Analysis
Data will be analyzed using NVivo 11 (QSR International). The
framework method [46] will be employed, which combines
deductive analysis of a priori themes identified in the evidence
synthesis, the quantitative analysis, and through expert
consultation, with inductive analysis of themes that emerge
from the data. Analysis comprises a 5-stage process of
scaffolding (identifying and extracting themes), indexing
(labeling and sorting data to test the framework), coding (coding
the data to the framework), descriptive analysis (categorizing
and classifying data into higher order themes), and explanatory
analysis (detecting thematic patterns and relationships). Each
group of participants will be analyzed separately before
cross-group analyses will be undertaken to triangulate the
qualitative data. Areas of convergence and divergence within
and across the 3 groups of data will be explored, and possible
explanations for contradictory findings will be proposed. To
ensure dependability and credibility [47], the key steps of the
analysis will be conducted by at least two researchers, and the
framework will be reviewed regularly by the project team and
PPI panel.
Results
The study was funded for 2 years, from September 2017 to
September 2019. Data collection is ongoing in the qualitative
workstream and is expected to be completed by the end of
December 2018.
In the later stages of analysis, the findings from the qualitative
study will be merged with quantitative analyses using
established integration techniques such as comparison matrices
to validate, confirm, or refute findings, and joint data displays
[48]. These analyses will be used by the project team to create
a logic model drawing on process evaluation methodology [49].
The model will delineate how diabetes contributes to health
inequalities in people with SMI and diabetes, exploring the
relationship between health care provision and inequalities.
Analytic rigor will be assured through regular discussion of
analytic strategies with the project team, study steering
committee, and PPI group.
Findings will be considered in 2 multistakeholder workshops
involving service users, family members, researchers, clinicians,
commissioners, health service managers, and representatives
from third sector organizations to develop recommendations to
improve diabetes care for people with SMI. The first workshop
will review the merged findings, identify further analyses that
can be conducted, and will create draft recommendations to
improve health care. The second workshop will use the final
analyses to refine the draft recommendations and to design and
assess the feasibility of interventions or care pathways where
the need for these has been identified empirically.
A range of channels will be used to communicate study findings
to participants, stakeholders, and likely beneficiaries of the
research. Key audiences will include patients, family members,
health care staff, policy makers, voluntary and commercial
sector organizations, and researchers. Representatives from
these sectors will be invited to a dissemination event at the end
of the study.
Research outputs will take the form of written reports, journal
articles, oral presentations, and content distributed through
international, national, and local networks, websites, and social
media.
Discussion
People with SMI face significant health inequalities compared
with the population as a whole, experiencing poorer physical
health and having a reduced life expectancy of 15 to 20 years.
Diabetes contributes to this inequality, occurring 2 to 3 times
more often in people with SMI. Although various
sociodemographic, genetic, illness, and health care–related
factors are thought to increase the risk of developing the
condition, the relative influence of these factors, and how they
might interrelate, remains poorly understood. Furthermore,
evidence suggests that people with comorbid SMI and diabetes
experience poorer diabetic outcomes than those without SMI.
This research will provide greater understandings of why people
with SMI are more at risk of developing diabetes and why their
diabetic outcomes may be poorer than those without SMI.
Associations between diabetes screening, monitoring and
management, and health outcomes will be investigated to
identify interventions with the potential to improve outcomes
in this population. In addition, exploring the health care needs
and health care delivery concerns of people with comorbid SMI
and diabetes, relatives or friends who support them, and health
care staff will enable the development of a more comprehensive
understanding of the factors that contribute to poor outcomes
and the drivers of improved health outcomes in SMI and
diabetes.
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